OC-0059 Stereotactic radiotherapy for oligoprogressive NSCLC: clinical scenarios affecting survival

Optimizing Patient Selection in Stereotactic Ablative Radiotherapy for Early Stage NSCLC through Comparative Effectiveness Research

Stereotactic Radiosurgery/Radiotherapy: A Historical Review

"Stereotactic" is an exact radiotherapy treatment modality which implements invasive and non-invasive facilities for improving precise dose delivery. Stereotactic refers to three-dimensional localization of a specific point in space by a unique set of coordinates that relate to a fixed external reference frame. An accurate delivery of radiation is attainable using these techniques with high pre...

Lung stereotactic body radiotherapy for early-stage NSCLC in patients with prior pneumonectomy: a case report.

Stereotactic body radiotherapy (SBRT) has become the standard of care for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC). A paucity of published data exists regarding the safety of SBRT use in patients with prior pneumonectomy. This report describes 2 patients with NSCLC and prior pneumonectomy who were treated with lung SBRT and experienced a favorable treatm...

Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer

Maintenance pemetrexed offers survival benefit with well-tolerated toxicities for advanced non-squamous non-small cell lung cancer (NSCLC). We present 3 consecutively enrolled patients with advanced non-squamous NSCLC, receiving stereotactic ablative radiotherapy (SABR) for oligoprogressive disease during maintenance pemetrexed. All of them had sustained local control of thoracic oligoprogressi...

Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT).

BACKGROUND The selection of patients for oligometastasis-directed ablative therapy remains a challenge. The authors report on clinical and molecular predictors of survival from a stereotactic body radiotherapy (SBRT) dose-escalation trial for oligometastases. METHODS Patients who had from 1 to 5 metastases, a life expectancy of >3 months, and a Karnofsky performance status of >60 received esc...